key: cord-0955358-tzuas2bc
authors: Dewi, Rismala; Kaswandani, Nastiti; Karyanti, Mulya Rahma; Setyant, Darmawan Budi; Pudjiadi, Antonius Hocky; Hendarto, Aryono; Djer, Mulyadi M.; Prayitno, Ari; Yuniar, Irene; Indawati, Wahyuni; Prawira, Yogi; Handryastuti, Setyo; Sjakti, Hikari Ambara; Hidayati, Eka Laksmi; Muktiarti, Dina; Soebadi, Amanda; Puspaningtyas, Niken Wahyu; Muhaimin, Riski; Rahmadhany, Anisa; Octavius, Gilbert Sterling; Puspitasari, Henny Adriani; Jasin, Madeleine Ramdhani; Tartila, Tartila; Putri, Nina Dwi
title: Mortality in children with COVID-19: Lessons learned from a tertiary referral hospital in Indonesia
date: 2021-04-20
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.04.019
sha: 098a42aa1650b893b812c466c6f8a3c9ea03cdfe
doc_id: 955358
cord_uid: tzuas2bc

Background The incidence of COVID-19 is still rapidly increasing, but little is known about the prevalence and characteristics of fatal cases in children in Indonesia. This study aims to describe the characteristics of pediatric COVID-19 cases with fatal outcomes in Indonesia's tertiary referral hospital. Methods This is a cross-sectional study with data collected from the medical records of COVID-19 patients admitted to Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from March to October 2020. Results During the study period, 490 patients were admitted and diagnosed with suspected and probable COVID-19. Of these patients, 50 (10.2%) were confirmed to have COVID-19, of which 20 (40%) patients with positive tests for SARS-CoV-2 had a fatal outcome. The fatality was higher in patients ≥10 years old, categorized with severe disease upon admission, with PaO2/FiO2 ratios of ≤300 mmHg and chronic underlying diseases. The most common clinical manifestations were generalized symptoms, while acute respiratory distress syndrome (8/20) and septic shock (7/20) were the two most common causes of death. Increased procalcitonin, D-dimer, lactate dehydrogenase, and presepsin levels were found in all fatal COVID-19 cases. One patient met the criteria of multisystem inflammatory syndrome in children (MIS-C). Conclusion Our work highlights the high mortality rate in pediatric patients positive for the COVID-19 test. Further studies are needed to understand better the role of SARS-CoV-2 in elaborating the mechanisms leading to death in children with comorbidities.

The novel coronavirus (SARS-CoV-2) was first reported in Wuhan, Hubei Province, China, in December 2019. The disease caused by this virus later became known as COVID-19 (WHO, 2020a) . Most reports have indicated that children and adolescents comprise a small proportion of confirmed cases and that these populations are less likely than adults to be severely affected (Dong et al., 2020a; Castagnoli et al., 2020; Rodriguez-Morales et al., 2020; Ludvigsson, 2020) . Furthermore, studies report a good health status in children with underlying chronic conditions and those on immunosuppressive treatment (Di Giorgio et al., 2021; Nicastro et al., J o u r n a l P r e -p r o o f We collected data from the medical records of suspected and confirmed pediatric COVID-19 patients admitted to Dr. Cipto Mangunkusumo National Central Hospital, Jakarta, a tertiary referral hospital in Indonesia, covering the period from March 2020, when the first Indonesian COVID-19 case was announced, to October 2020 (WHO, 2020c) . Dr. Cipto

Mangunkusumo National Central Hospital also serves as a general hospital with 57 beds for neonatal intensive care units (31 beds for patients with suspected or confirmed COVID-19), 18 beds for pediatric intensive care units (12 beds for patients with suspected or confirmed , and 88 beds for the pediatric ward (12 beds for patients with suspected or confirmed . In 2020, 31,075 patients across all ages visited the emergency department, with 1,373 (4.41%) patients confirmed as positive for COVID-19. Demographic data (age, sex, weight, and height), status of COVID-19 (rapid antibody tests results, RT-PCR results, Ct values), signs and symptoms, comorbidities, pediatric intensive care unit (PICU) status, cause of deaths, and laboratory data were obtained.

We included all pediatric patients (0-18 years old) who had tested positive for COVID-19 infection using the reverse transcriptase-polymerase chain reaction (RT-PCR) from any sample involving a swab or other specimen and had a fatal outcome. Probable cases were excluded from this study. We used local guidelines to define probable cases as (1) A person who meets clinical criteria (three or more clinical signs and/or symptoms such as fever, cough, fatigue, headache, myalgia, sore throat, runny nose, dyspnea, anorexia, nausea, vomiting, diarrhea, or loss of consciousness) and has a history of close contact with probable cases, confirmed; or related to the COVID-19 cluster cases; (2) Suspected cases with radiological features suggestive of and (3) A person with acute anosmia or ageusia with no other cause identified (Kementrian Kesehatan Republik Indonesia, 2020).

Patients were classified according to their clinical presentations upon admission as (1) asymptomatic (absence of signs and symptoms associated with COVID-19, normal clinical J o u r n a l P r e -p r o o f imaging, but positive ribonucleic acid SARS-CoV-2 test); (2) mild (presence of symptoms limited to upper respiratory tract infections, including fever, fatigue, myalgia, cough, sore throat, runny nose or nasal congestion, or gastrointestinal symptoms, including nausea, vomiting, and abdominal pain, with normal lung auscultation); (3) moderate (presence of symptoms mentioned in the mild category together with clinical signs and symptoms of pneumonia but without hypoxemia); (4) severe (presence of signs and symptoms mentioned above together with dyspnea, central cyanosis, and oxygen saturation of <92%); and (5) critical (presence of acute respiratory distress syndrome, respiratory failure, encephalopathy, myocardial injury, coagulation dysfunction, and acute kidney injury) (Dong et al., 2020b) .

The Centers for Disease Control and Prevention (CDC) criteria for MIS-C associated with COVID-19 was used in this study. The criteria classified patients as having MIS-C if: (1) they were younger than 21 years old; (2) they had a fever and elevated inflammatory markers were present; (3) A clinically severe illness requiring hospitalization and had multisystem (two or more) organ involvement (cardiac, renal, respiratory, hematological, gastrointestinal, dermatological, or neurological) ; (4) other plausible alternative diagnoses had been excluded; and (5) they had a positive RT-PCR, serology, or antigen test or COVID-19 exposure within the past four weeks before the onset of symptoms (CDC, 2020). The CDC criteria were chosen because it was released earlier than the World Health Organization criteria. Furthermore, the CDC criteria were used since our clinicians were more familiarized with them.

All naso-oropharyngeal and sputum/endotracheal tube aspirate samples were tested for the presence of SARS-CoV-2, and the N gene Cq was used as the parameter for the RT-PCR target. The standard protocol for obtaining the samples was via naso-oropharyngeal swabs with a minimum of two samples within a one-day interval. If the samples were positive, subsequent J o u r n a l P r e -p r o o f samples were obtained every 5-7 days until conversion was achieved. Ct values above 40 (detection limit) were reported as negative, while Ct values below 37 were considered positive (He et al., 2020) . A medium load (Ct value of 37 to 40) requires confirmation via at least one repeat sample in our institution.

The data is presented in median and range format without any statistical tests being used in this study.

cases. Out of these, 50 (10.2%) cases were confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) tests. Among the confirmed cases, 20 patients (40%) died and were included in this analysis. The mortality rate in confirmed pediatric COVID-19 patients was 40%.

There was no difference in mortality between males and females in patients positive for COVID-19 (Table 1) . Most (18/20) of the patients had previous exposure to healthcare facilities or professionals. The highest mortality came from patients older than 10 years old and those placed in the severe category upon admission. Most (12/20) patients presented with generalized or systemic symptoms such as fever, malaise, myalgia, and fatigue. Kidney diseases, such as nephritic lupus with secondary hypertension, acute kidney failure, and chronic kidney disease, were the most common comorbidity, found in 8/20 patients, with four patients requiring dialysis. Three of those patients were previously on chronic dialysis, while one of them was receiving continuous renal replacement therapy regularly before COVID-19 diagnosis. Multiple (two or more) 16

Exposure to healthcare facilities or professionals, (N=20) 18

History of contact with suspected or confirmed cases, (N=20) 2

Shock, (N=20) Septic 9

Not in shock 7

Hypovolemic 4

Septic shock was the most common type of shock (9/20) seen among subjects, and acute respiratory distress syndrome (ARDS) was the most common cause of death (8/20). It took three days from admission and 5.5 days from the onset of the first clinical manifestations of COVID-19 for their conditions to worsen ( Table 2) SARS-CoV-2 RNA was detected in a sputum sample/endotracheal tube aspirate in one patient and naso-oropharyngeal swab specimens in the remaining patients. The median first sample Ct value was 33.2, with a range of 21.41 to 36.26.

All patients were admitted with increased procalcitonin, D-dimer, lactate dehydrogenase, and presepsin levels. White blood cells, platelet counts, lactic acid, prothrombin time, and creatinine levels on day one and day three were normal in most patients (Table 3) .

Detailed clinical characteristics of each subject are described in Table 4 . Two cases were asymptomatic (cases 1 and 9), as they were initially admitted for severe burns affecting body surface areas of 59% and 45%, respectively, and were later diagnosed with COVID-19 by RT-PCR testing. Notably, all of the patients had more than one comorbidity.

Echocardiography was performed on one patient (case 5) and showed pericardial effusion with an ejection fraction of 77%. Two cases presented with moderate illness (cases 3 and 10) and

passed away due to surgical complications related to bleeding. Our preliminary findings J o u r n a l P r e -p r o o f showed that increments in creatinine levels between day one and day three led to prolonged hospitalization, except for one case (case 13). This patient showed a decrement in creatinine level, although no association or significance can be inferred.

We studied the clinical and laboratory characteristics of pediatric COVID-19 patients with fatal outcomes. The proportion of COVID-19-associated deaths in this study is higher than the COVID-19 case fatality rate in 42 states in the USA, which reported mortality rates of 0 to 0.23% as of October 22, 2020 (AAP, 2020). It is also higher than the 1.9% nationwide case fatality rate reported in Indonesia (Pulungan, 2020) . Since our center is a national tertiary referral hospital, our patients often present one or more pre-existing underlying chronic diseases that will affect their prognoses and mortality. Nearly all of the patients in this study had at least one comorbidity, with the most common being kidney disease in 8/20 cases, followed by malignancy and cardiovascular disease in 6/20 cases each. Chronic kidney disease is associated with a poorer prognosis due to disturbances in the innate and adaptive immune responses, rendering such patients more susceptible to all infections (Gagliardi, 2020) . Our findings differ from those of another study which reported that 86% of patients had at least one comorbidity, with the most prevalent pre-existing conditions being medically complex conditions (40%), immunosuppression or malignancy (23%), and obesity (15%). There were two deaths reported in this study, and all of the two patients who died had comorbidities (Shekerdemian et al., 2020) . J o u r n a l P r e -p r o o f Obesity and overweight are the two comorbidities frequently mentioned as risk factors for mortality in COVID-19 or MIS-C in pediatric patients (Jiang et al., 2020; Ahmed et al., 2020) . However, underweight is a comorbidity that has not yet been discussed in detail, especially in the pediatric population. Studies done in the adult population show conflicting results; one study found that underweight individuals tended to trend towards an increased risk of contracting the infection, but this trend was not statistically significant (Jung et al., 2020) .

Another retrospective cohort study of 2,466 hospitalized adults found that underweight individuals had a borderline statistically significant association with an increased risk for death or intubation (Anderson et al., 2020) .

Another reason accounting for the high mortality rate seen in this study is the severity of clinical manifestations upon presentation. One review found that non-mild disease, defined as pneumonia or need for hospitalization, accounted for 33.3% cases. In contrast, more severe illness accounted for 9.1% of cases, which contrasts with the 55% and 35% rates, respectively, that were observed in our study (Anderson et al., 2020 Toubiana et al., 2020) . While this number is slightly lower in our study (10/20), it is lower because six parents signed 'do not resuscitate' forms, making treatment suboptimal for these patients. Other reasons that could explain the high mortality rate are overcrowding in our hospital wards due to the sudden surge of new COVID-19 cases coupled with the lack of human resources initially to combat the pandemic.

The median first-sample Ct values in our study were 33.2, similar to the values found in one study in China that examined ten pediatric patients, which found a median Ct value of 33.5 (He et al., 2020) . Low SARS-CoV-2 Ct values were associated with the increased likelihood of progression to more severe disease, increased mortality, and the presence of biochemical and hematological markers (Rao et al., 2020) . According to one study, our study's median Ct value is classified as a low viral load (30-39.9) (Karahasan et al., 2020) .

In our study, mortality also tended to be higher in patients with PaO2/FiO2 ratios ≤ 300 mmHg, in line with other studies done in Europe (Wendel et al., 2020) . Our study produced results similar to those of other meta-analyses (Elshazli et al., 2020; Henry et al., 2020) and one review study (Letícia et al., 2020) , which reported that increased D-dimer, fibrinogen, procalcitonin, CRP, and ferritin levels, as well as low hemoglobin levels were associated with severe disease and mortality. Although increased WBC counts were consistently cited as one of the significant predictors for severe disease (Elshazli et al., 2020; Henry et al., 2020; Letícia et al., 2020) , nine of our patients had normal WBC counts, which might be explained by the inclusion of six patients with hematological malignancies with the potential to impair WBC counts.

One patient (case 18) met the CDC criteria for MIS-C, meaning that a positive RT-PCR, serology, or antigen test or COVID-19 exposure within the past four weeks before the onset of symptoms was required (Jiang et al., 2020; Ahmed et al., 2020 Indonesia, 2020). Antivirals were also given to some patients due to underlying comorbidities resulting in immunocompromised conditions. As the knowledge of COVID-19 is always evolving, the knowledge of using IVIG, steroids, and low molecular weight heparin as prophylaxis of thrombosis was not widespread early in the disease. It hence reflected the lack of specific treatment towards COVID-19. This study also shows that most patients were exposed to healthcare facilities. This highlights the urgent need for infection prevention education protocols, especially for children with chronic medical conditions necessitating multiple hospital visits.

There are several limitations to our study. First, since Dr. Cipto Mangunkusumo

Hospital is a referral hospital for managing COVID-19 patients, especially those with comorbidities, the mortality rate for pediatric COVID-19 cases reported in this study cannot be extrapolated to other hospitals, cities, or regions in the country. Secondly, we could not establish significant associations between several of the variables mentioned above and mortality as well as MIS-C. Thirdly, we could not determine whether the cause of death was attributable to COVID-19 or underlying comorbidities. Lastly, we did not check several laboratory panels, such as interleukins and other cytokines, to measure the severity of COVID-19. Nevertheless, despite these limitations, our study has revealed high mortality in pediatric COVID-19 patients. To our knowledge, this study is the first to describe the clinical characteristics of an Indonesian population.

This study described cases of mortality in pediatric patients with positive tests for COVID-19: a higher proportion of deaths were observed in patients older than 10 years old, with severe manifestations upon admission, and with PaO2/FiO2 ratios ≤ 300 mmHg. This is the first study in Indonesia that highlights COVID-19-associated mortality in children.

However, further multi-center studies and better intervention and management studies are required to optimize public health measures, especially for pediatric patients with severe and critical COVID-19. Further studies are also needed to understand better the role of SARS-CoV-2 in supporting the mechanisms leading to mortality in children with associated comorbidities. 

The Ethics Committee approved this study of the Faculty of Medicine, Universitas Indonesia (no. 596/UN2.F1/ETIK/PPM.00.02/2020).

This study is funded by a research grant from Cipto Mangunkusumo Hospital.

State-Level Data Report

Multisystem inflammatory syndrome in children: A systematic review

Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection

Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic

COVID-19 deaths in children: comparison with all-and other causes and trends in incidence of mortality

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents

Inflammatory Syndrome In Children (MIS-C)

Health status of children with chronic liver disease during the SARS-CoV-2 outbreak: results from a multicentre study

Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in china

Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients

Ten key points about COVID-19 in children: The shadows on the wall

COVID-19 and the Kidney: From Epidemiology to Clinical Practice

Temporal dynamics in viral shedding and transmissibility of COVID-19

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

COVID-19 and multisystem inflammatory syndrome in children and adolescents

Association between Body Mass Index and Risk of Coronavirus Disease 2019 (COVID-19): A Nationwide Case-control Study in South Korea

Relationship of the cycle threshold values of SARS-CoV-2 polymerase chain reaction and total severity score of computerized tomography in patients with COVID 19

Pedoman Pencegahan Pengedalian Coronavirus Disease (COVID-19). 2020. [online] Kementerian Kesehatan Republik Indonesia

COVID-19: Review and hematologic impact

Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults

Impact of the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak on Pediatric Liver Transplant Recipients in Lombardy, Northern Italy

Indonesia set to have world's highest rate of child deaths from COVID-19

Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19

Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS) -guidance for clinicians

Hyperinflammatory shock in children during COVID-19 pandemic

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Characteristics and Outcomes of Children

Infection Admitted to US and Canadian Pediatric Intensive Care Units

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic

Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort

COVID-19) Dashboard. 2020a. [online] Covid19.who.int

Multisystem inflammatory syndrome in children and adolescents Temporally related to COVID-19

room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescentswith-covid-19>

WHO. Coronavirus Disease 2019 (COVID-19) Situation Report -1. 2020c

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

We would like to thank Cipto Mangunkusumo Hospital Director, all patients and their families, pediatric residents of the University of Indonesia, and the Kiara Ultimate medical team for their help and support.